Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC

NCT07561983 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Stage III Non-small Cell Lung Cancer
Tislelizumab
Chemotherapy
Chemoembolization, Therapeutic
Conversion Therapy

Interventions

DRUG: Tislelizumab
DRUG: Intravenous Chemotherapy
PROCEDURE: Bronchial Artery Chemoembolization (BACE)

Sponsor

Sichuan Cancer Hospital and Research Institute